Developing New Medicines Through Artificial Intelligence
On September 30, 2012, a computer program named “AlexNet” won an international competition and ushered in a new age of artificial intelligence (AI)....
On September 30, 2012, a computer program named “AlexNet” won an international competition and ushered in a new age of artificial intelligence (AI)....
While many biopharmaceutical companies are built to fulfil a need, Resilience was built to serve innovation. Founded during the COVID-19 pandemic in...
Biomanufacturing safety and efficacy depend on well-controlled, compliant manufacturing processes. Can a virtual model truly give biomanufacturing...
Are you an innovator company looking for a reliable and innovative partner? You have come to the right place.
Resilience and Pluristyx have entered a strategic collaboration to accelerate and simplify the transition of promising iPSC-derived therapies from...
Event Overview: Join us for an informative webcast with industry experts as they address critical challenges in viral vector manufacturing that...
The proliferation of recombinant protein therapies has driven the need for new capacity in the biotherapeutic manufacturing space. Monoclonal...
How Early-Phase Companies Can Future-Proof Their Cell Therapies The following was extracted from a conversation with Eytan Abraham “Q: How should...